New triple drug combination shows promise in hepatitis C infected patients

Posted by on April 14, 2016 12:12 pm
Categories: health

New data demonstrates a high sustained virologic response (SVR) at 12 weeks from the all-oral combination of sofosbuvir/velpatasvir and experimental compound GS-9857 in patients with the hepatitis C virus (HCV).

Leave a Reply

Your email address will not be published. Required fields are marked *